PT-141
PT-141Melanocortin agonist studied in sexual-response research.
Also known as: Bremelanotide
Overview
PT-141 (bremelanotide) is a melanocortin-receptor agonist studied in central-nervous-system and sexual-response research models. It is derived from the melanocortin peptide family.
A melanocortin-receptor agonist (bremelanotide) derived from Melanotan II, studied — and FDA-approved as Vyleesi — for sexual desire. Unlike vascular ED treatments, it acts centrally in the brain to influence arousal pathways in both men and women.
Activates melanocortin-4 receptors in the central nervous system, influencing arousal pathways independent of the vascular system.
Molecular information
Bremelanotide; a cyclic heptapeptide metabolite of Melanotan II lacking the tanning emphasis.
Pharmacokinetics
Illustrative relative-concentration model derived from published pharmacokinetic research. Curve is normalized and provided for educational comparison only — not a dosing schedule.
Research applications
- Central sexual-response research
- Melanocortin-pathway studies
- Neurobehavioral investigations
Research protocols
Protocols summarized from published research models. Provided for scientific reference only — not dosing guidance for human use.
Observed effects timeline
Aggregated observations reported across research literature. Timing and magnitude vary by model and are not a guarantee of outcome.
Acute
Arousal/desire effects reported within hours of administration.
As-needed
Used episodically rather than continuously in research and approved labeling.
Research compatibility
Describes how compounds are studied alongside one another in the literature. Not a recommendation to co-administer.
Melanotan II
Overlapping melanocortin activity — avoid redundancy.
Oxytocin
Complementary in sexual-behavior research contexts.
Blood-pressure agents
Transient blood-pressure increases are reported.
BPC-157
No known interactions. Different mechanisms of action - PT-141 for sexual function, BPC-157 for tissue repair.
How to reconstitute
Reconstitute with bacteriostatic water, swirl gently, and refrigerate. Avoid shaking to preserve the peptide.
- 1Allow the vial to reach room temperature (15–20 minutes).
- 2Swab the stopper with alcohol and let it air dry.
- 3Add bacteriostatic water slowly down the vial wall.
- 4Swirl gently until dissolved into a clear solution.
- 5Refrigerate at 2–8 °C and protect from light.
Quality indicators
Uniform white powder
Lyophilized cake should be white to off-white without discoloration.
Clear solution
Reconstitutes to a clear, colorless, particle-free solution.
Cold-chain integrity
Reconstituted solution requires 2–8 °C storage.
Slight clumping
Small clumps that dissolve completely with gentle swirling are acceptable — shipping can cause minor compaction.
Collapsed or melted appearance
Powder that looks collapsed, melted, or stuck to the vial walls may have been exposed to heat in transit.
Cloudy after reconstitution
Persistent cloudiness, particles, or precipitate after gentle mixing can indicate a degraded or contaminated peptide.
Reported observations & safety
Safety signals reported in the research literature. Compiled for scientific awareness — not medical advice.
- Nausea, flushing, headache, and transient blood-pressure elevation are the most commonly reported signals.
- An FDA-approved compound (Vyleesi) with a defined human safety profile.
References & further reading
Bremelanotide (PT-141) for sexual dysfunction (clinical)
Clinical research on the melanocortin agonist's central effects on sexual desire and arousal.
View studyTopics
This entry is provided for educational and informational purposes only. It is not medical advice, a dosing protocol, or a claim of therapeutic benefit. Research compounds are supplied strictly for laboratory and research use — not for human or veterinary consumption.
Approved for one or more clinical indications by a major regulator.
PT-141 is stocked as a research-grade compound, ≥99% by HPLC, third-party verified.
View in catalogue